Study of AROSOD-1 in Adult Participants With Amyotrophic Lateral Sclerosis (ALS)

Inclusion Criteria

• •Diagnosis of ALS based on source-verifiable medical record and meets the Gold Coast Criteria
• •Pathogenic or likely pathogenic SOD1 mutation based on source-verifiable medical records or genetic testing during Screening
• •Slow Vital Capacity (SVC) ≥ 50% of predicted value adjusted for sex, age, and height (from a sitting position) at Screening
• •Body Mass Index (BMI) ≥ 18.0 kg/m2 at Screening
• •Able to complete at least 6 months of follow-up
• •If taking any medication or supplement to treat ALS or ALS symptoms, must be on stable dose for ≥ 4 weeks prior to Day 1 and expected to remain at that dose until final study visit and not expected to start these medications after the first dose of ARO-SOD1
• •Able and willing to provide written informed consent and to comply with all study assessments
• •Participants of childbearing potential must agree to use highly effective contraception in addition to a condom during the study and for at least 90 days following the end of study or last dose of study drug, whichever is later. Males must not donate sperm and females must not donate eggs during the study and for at least 90 days following the end of the study or last dose of study drug, whichever is later.